ClinicalTrials.gg

Hypoglycemia clinical trials

Its pipeline, or its studies — you choose. Free with an account during the beta.

The registry lists 706 studies for Hypoglycemia across more than 10 countries. 94 are recruiting or about to start. 221 of them are mainly about Hypoglycemia (how this is decided). Per ClinicalTrials.gov, last updated 2026-11-12. Counting its 2 narrower conditions too, such as Congenital Hyperinsulinism: 730 studies, 95 open.

ClinicalTrials.gov finds 966 studies for Hypoglycemia. How that becomes 706 here

This page counts the studies the registry files under Hypoglycemia, and those it files under no condition that list Hypoglycemiathemselves. Each study its search finds is placed by how the registry filed it and by the conditions it lists. ClinicalTrials.gov counts as of Nov 8, 2026. How condition pages count

  1. 966Found by its condition searchIt reads the conditions a study lists and their synonyms, and also titles and keywords.
  2. −23Filed under a narrower condition, counted on its own pageCongenital Hyperinsulinism 22 · Nesidioblastosis 1
  3. −50List Hypoglycemia as a condition, but the registry did not file them under itMost often written as “Neonatal Hypoglycemia” (15), “Hypoglycemia Unawareness” (12), and “Fear of Hypoglycemia” (5). The registry filed them under other conditions only, most often Diabetes Mellitus, Type 1 (20) and Premature Birth (7).
  4. −187Match it another way118 name it in the title, 17 in a keyword, and 52 by a synonym or other text the search reads.
  5. 706The count on this page42 of them list Hypoglycemia in their own words; the registry filed them under no condition.

Status

Completed
457
Recruiting
59
Terminated
54
Status unknown
45
Withdrawn
32
Not yet recruiting
27

Phase

Phase 2
117
Phase 1
63
Phase 4
53
Phase 3
53
Early Phase 1
15

Where

United States
294
Canada
72
Denmark
63
United Kingdom
43
Switzerland
34
France
33

Who develops what

Add Hypoglycemia to watchlistPro · free during the betaEvery Monday by email · turn it off any time

Every program with a company-led study here in the last two years, whatever its size: 7 programs from 7 companies, 3 with this as their studies’ main aim; 1 with a live phase 3 study; 4 primary completions in the next 12 months.

Comparator & background therapies

What other companies’ phase 2+ studies give as the comparator or the background here (its leading trial sponsor and partners left out): a sign of what new drugs are measured against, not by itself the standard of care, its prescriptions or its market.

DrugLeading trial sponsor · rightsCompanies, last 5 years
insulin degludecRecent, limited
Evidence
  • NCT07215312 · Eli Lilly and Company · Phase 2 · live · comparator · “Degludec” · registered Oct 2025
Novo Nordisk A/S93% of its industry studiesUS: Novo Nordisk A/S (FDA 2015)EU: Novo Nordisk A/S (EMA 2013)11 study

Programs

“Meets, by arms” reads each study’s arms: vs its arm against the therapy’s; + X vs a combination against it; added to it plus the therapy against the therapy; studied with given together only. The next primary completion is the next phase-3 study’s when there is one.

In phase 3Company
avexitide☆ Track1 live phase-3 study: NCT06747468Amylyx Pharmaceuticals Inc.

The 1 in phase 3 with the nearest primary completion, of 7 programs — sign in to see the whole list, free: filter by phase and aim, sort by late development, direct comparisons or the next primary completion.

Primary completion in the next 12 months (4)

Live phase 2 and 3 studies of these programs. Primary completion is when the main measure’s data collection ends, as the registry states it (most are estimates); results come later, if they are announced.

  • Nov 2026 est.LY3938577 · Eli Lilly and Company · Phase 2 registry mapping only+ LY3938577 vs insulin degludecNCT07215312 A Study of LY3938577 in Participants With Type 2 Diabetes Previously Treated With Basal Insulin — primary endpoint: Change from Baseline in Glucose Time in Range Between 70 and 180 mg/dL Inclusive (Non-Inferiority Analysis) · 100 enrolled
  • 8 Apr 2027 est.VCT220 · Corxel Pharmaceuticals · Phase 2 registry mapping onlyNCT07340320 A Study of CX11 Tablets in Patients With Type 2 Diabetes Mellitus — primary endpoint: Change in Glycosylated hemoglobin, Type A1C (HbA1c) from baseline · 251 enrolled
  • Oct 2027 est.mizagliflozin · Vogenx, Inc. · Phase 2 main aimNCT07760961 Effect of Mizagliflozin on Hypoglycemia in Patients With Post-Bariatric Hypoglycemia — primary endpoint: Number of combined Level 2 (as measured by self-monitored blood glucose) and Level 3 hypoglycemic events (as measured by diary entry and adjudicated) · 36 enrolled

1 more — sign in to see them all, free.

Read from ClinicalTrials.gov, industry-led studies. Main aim: this is the study’s judged main condition; named, not the main aim: the sponsor names it, the study is about something else; registry mapping only: only the registry’s mapping put it here. Leading trial sponsor is the company leading the most industry studies of a drug, a measure of trial activity, not of rights. US and EU rights, and Approved: from the regulators’ records (FDA’s Drugs@FDA via openFDA; EMA’s medicines data) — the holder of a marketed or authorized original, generics and other companies’ versions; not rights elsewhere, nor approval for this condition. Phase 4 trial recorded, where neither lists it: a phase 4 study exists somewhere. Not read yet: labels by indication, exclusivity, licenses, line of therapy, academic comparators, sales.

What is being tested here

Drugs under test in Hypoglycemia studies, those with the most open studies first. Medicines only given beside them are not counted. How drugs are counted

Drug classes tested here SGLT2 inhibitors 1 open · GLP-1 receptor agonists 13 · DPP-4 inhibitors 12 · Bronchodilators 5 · Opioid antagonists 4

Coming up

40studies finish main data collection within a year1 of them phase 3

Studies recruiting or running, from their records. “Main data collection” ends at the primary completion date, the sponsor’s own estimate, which often moves.

The 10 nearest, phase 3 first

Who these studies take

Of the 59 Hypoglycemia studies recruiting now, 23 (39%) set no upper age limit and 31 (53%) stop at 75 or younger. 18 (31%) take children under 18. 3 (5%) are for women only and 0 (0%) for men only; 14 (24%) take healthy volunteers.

Recruiting studies that take each age, of 59
AgeWomenMen
1012 (20%)12 (20%)
1849 (83%)46 (78%)
3047 (80%)44 (75%)
4047 (80%)44 (75%)
5043 (73%)41 (69%)
6541 (69%)39 (66%)
7531 (53%)29 (49%)
8527 (46%)25 (42%)

Across all 706 studies, recruiting or not: 58% stop at 75 or younger and 45% at 65; 23% take children; 3% are for women only and 4% for men only; 21% take healthy volunteers. From each study’s registry entry; the criteria on its page decide.

How long Hypoglycemia studies take

Of 24 phase 2 interventional studies under Hypoglycemia, half reached primary completion within 12 months of starting, counting those still running.

Start to primary completionEvery sponsorIndustryNon-industry
Phase 120 mo7–105 · 21 studies——
Phase 212 mo8–31 · 24 studies——
Phase 314 mo4–29 · 17 studies——
Phase 420 mo5–35 · 18 studies——
Interventional, no phase17 mo7–33 · 175 studies—18 mo8–33 · 169 studies
Observational22 mo12–52 · 53 studies—22 mo12–52 · 52 studies

Each figure is the month by which half the studies had reached primary completion, with the range in which the middle half did. Studies still running count until their last registry update; studies that stopped early are left out. Phase 1 includes early phase 1; observational means prospective or not stated, as retrospective and cross-sectional studies date a window of data rather than a study. How these figures are worked out

What changed recently

From the registry's own updates since Oct 18, 2026.

Studies

Recruiting first, then most recently updated. Showing 50 of 706. Browse all 706 → or search them.